{"id":62563,"date":"2026-10-16T19:18:27","date_gmt":"2026-10-16T19:18:27","guid":{"rendered":"https:\/\/cp.snarskis.lt\/index.php\/2026\/10\/16\/omass-therapeutics-pritrauke-275-mln-euru-ka-tai-reiskia-naujiems-mazuju-molekuliu-vaistams\/"},"modified":"2026-10-16T19:18:27","modified_gmt":"2026-10-16T19:18:27","slug":"omass-therapeutics-pritrauke-275-mln-euru-ka-tai-reiskia-naujiems-mazuju-molekuliu-vaistams","status":"publish","type":"post","link":"https:\/\/cp.snarskis.lt\/index.php\/2026\/10\/16\/omass-therapeutics-pritrauke-275-mln-euru-ka-tai-reiskia-naujiems-mazuju-molekuliu-vaistams\/","title":{"rendered":"\u201eOMass Therapeutics\u201c pritrauk\u0117 275 mln. eur\u0173: k\u0105 tai rei\u0161kia naujiems ma\u017e\u0173j\u0173 molekuli\u0173 vaistams"},"content":{"rendered":"

275 mln. eur\u0173 finansavimas<\/h2>\n

Jungtin\u0117s Karalyst\u0117s biotechnologij\u0173 bendrov\u0117 \u201eOMass Therapeutics\u201c, \u012fkurta kaip Oksfordo universiteto at\u0161aka, prane\u0161\u0117 u\u017ebaigusi 275 mln. eur\u0173 C serijos investicij\u0173 etap\u0105. Bendrov\u0117 teigia, kad finansavimas buvo pertekli\u0161kai pasira\u0161ytas, o tai da\u017enai signalizuoja didel\u0119 investuotoj\u0173 paklaus\u0105 ir pasitik\u0117jim\u0105 klinikine strategija.<\/p>\n

Investicij\u0173 etap\u0105 kartu ved\u0117 nauji investuotojai Bain Capital Life Sciences, Forbion ir Novo Holdings. Prie etapo taip pat prisijung\u0117 Janus Henderson Investors, SV Health Investors ir Jefferson Life Sciences, o dalyvavim\u0105 t\u0119s\u0117 ir ankstesni investuotojai, tarp j\u0173 Syncona, Oxford Science Enterprises, GV, Northpond Ventures, Sanofi Ventures, British Business Bank bei Oksfordo universitetas.<\/p>\n

Kokius projektus stums \u012f priek\u012f?<\/h2>\n

Bendrov\u0117 nurodo, kad pagrindin\u0117 l\u0117\u0161\u0173 dalis bus skiriama pa\u017eangiausiai programai OMS1620, kuri kuriama kaip MC2 receptoriaus antagonistas. \u0160i\u0105 molekul\u0119 planuojama vesti per 2 faz\u0117s klinikinius tyrimus, orientuojantis \u012f \u012fgimt\u0105 antinks\u010di\u0173 hiperplazij\u0105 ir nuo AKTH priklausom\u0105 Ku\u0161ingo sindrom\u0105.<\/p>\n

\u201e\u0160is finansavimas sutampa su svarbiu m\u016bs\u0173 augimo etapu, kai OMS1620 judame \u012f klinik\u0105, o SLC15A4 inhibitorius ruo\u0161iasi sekti i\u0161 paskos\u201c, \u2013 sak\u0117 \u201eOMass Therapeutics\u201c generalin\u0117 direktor\u0117 Ros Deegan.<\/p>\n

\u201eTur\u0117dami nauj\u0173 ir esam\u0173 investuotoj\u0173 palaikym\u0105, \u012f\u017eengiame \u012f kit\u0105 faz\u0119 su i\u0161tekliais, kurie leid\u017eia paversti pasiekimus klini\u0161kai i\u0161siskirian\u010di\u0173 vaist\u0173 portfeliu pacientams\u201c, \u2013 prid\u016br\u0117 ji.<\/p>\n

Platforma ir rinka: kod\u0117l tai svarbu<\/h2>\n

\u201eOMass Therapeutics\u201c 2016 metais \u012fkurta siekiant komercializuoti profesor\u0117s Dame Carol Robinson laboratorijoje sukurtus natyviosios masi\u0173 spektrometrijos tyrimus. Bendrov\u0117 akcentuoja savo \u201eOdyssION\u201c platform\u0105, kuri jungia naujos kartos natyvi\u0105j\u0105 masi\u0173 spektrometrij\u0105, biochemijos metodus ir individualiai pritaikyt\u0105 chemin\u0119 sintez\u0119, kad taikinius b\u016bt\u0173 galima tirti j\u0173 \u201enat\u016bralioje\u201c biologin\u0117je aplinkoje.<\/p>\n

Pasak bendrov\u0117s, toks po\u017ei\u016bris turi pad\u0117ti tiksliau \u012fvertinti vaistini\u0173 molekuli\u0173 s\u0105veikas sud\u0117tingose taikini\u0173 ekosistemose ir taip didinti tikimyb\u0119, kad kandidatai bus s\u0117kmingi klinikoje. Investuotojams tai ypa\u010d aktualu d\u0117l bendros rinkos tendencijos: kapitalas vis labiau telkiamas \u012f platformas ir programas, kurios gali pasi\u016blyti ai\u0161k\u0173 diferenciatori\u0173, o ne vien\u0105 izoliuot\u0105 kandidat\u0105.<\/p>\n

\u201e\u201eOMass\u201c remiasi patyrusia komanda ir ai\u0161kia vizija, kaip sud\u0117ting\u0105 biologij\u0105 paversti pacientams svarbiais, i\u0161siskirian\u010diais vaistais\u201c, \u2013 sak\u0117 Bain Capital Life Sciences atstovas Evano Greifo.<\/p>\n

\u201eBendrov\u0117 \u0161i\u0105 vizij\u0105 \u012fgyvendina jud\u0117dama su OMS1620 ir pl\u0117sdama portfel\u012f endokrinologijoje bei imunologijoje. Matome reik\u0161ming\u0105 potencial\u0105 pagerinti gydym\u0105 pacientams, sergantiems \u012fgimta antinks\u010di\u0173 hiperplazija\u201c, \u2013 prid\u016br\u0117 jis.<\/p>\n

Bendrov\u0117 taip pat planuoja finansuoti ankstesn\u0117s stadijos portfel\u012f, \u012fskaitant pirmini\u0173 klinikini\u0173 duomen\u0173 generavim\u0105 SLC15A4 inhibitoriui, kuris vertinamas d\u0117l vilklig\u0117s ir kit\u0173 lig\u0173, susijusi\u0173 su interferono perprodukcija bei patogenine B l\u0105steli\u0173 aktyvacija.<\/p>\n

Platesniame kontekste toks finansavimo dydis i\u0161ry\u0161kina 2026 metais i\u0161liekant\u012f investuotoj\u0173 d\u0117mes\u012f Europos terapij\u0173 sektoriui, ypa\u010d kai kalbama apie klini\u0161kai art\u0117jan\u010dias programas ir ai\u0161kiai suformuluot\u0105 keli\u0105 iki 2 faz\u0117s rezultat\u0173. B\u016btent 2 faz\u0117s duomenys da\u017enai tampa l\u016b\u017eio ta\u0161ku, kai did\u017eiosios farmacijos bendrov\u0117s vertina licencijavimo ar \u012fsigijimo galimybes.<\/p>\n","protected":false},"excerpt":{"rendered":"

\u201eOMass Therapeutics\u201c pritrauk\u0117 275 mln. eur\u0173 C serijoje ir \u017eada spartinti OMS1620 bei SLC15A4 inhibitoriaus klinikin\u0119 pl\u0117tr\u0105.<\/p>\n","protected":false},"author":0,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[94],"tags":[47646,4093,47647,45385,6567,47645,1040],"miestas":[],"class_list":["post-62563","post","type-post","status-publish","format-standard","hentry","category-finansai","tag-bain-capital-life-sciences","tag-biotechnologijos","tag-forbion","tag-novo-holdings","tag-oksfordo-universitetas","tag-omass-therapeutics","tag-startuoliai"],"acf":[],"_links":{"self":[{"href":"https:\/\/cp.snarskis.lt\/index.php\/wp-json\/wp\/v2\/posts\/62563","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cp.snarskis.lt\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cp.snarskis.lt\/index.php\/wp-json\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/cp.snarskis.lt\/index.php\/wp-json\/wp\/v2\/comments?post=62563"}],"version-history":[{"count":0,"href":"https:\/\/cp.snarskis.lt\/index.php\/wp-json\/wp\/v2\/posts\/62563\/revisions"}],"wp:attachment":[{"href":"https:\/\/cp.snarskis.lt\/index.php\/wp-json\/wp\/v2\/media?parent=62563"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cp.snarskis.lt\/index.php\/wp-json\/wp\/v2\/categories?post=62563"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cp.snarskis.lt\/index.php\/wp-json\/wp\/v2\/tags?post=62563"},{"taxonomy":"miestas","embeddable":true,"href":"https:\/\/cp.snarskis.lt\/index.php\/wp-json\/wp\/v2\/miestas?post=62563"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}